Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.

The company has agreed to pay $2.2 billion to settle around 80,000 state court product liability cases alleging injury from Zantac (ranitidine), most of which had been consolidated in a Delaware ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

Over-the-counter treatment Zantac, known also by its non-commercial name ranitidine, was manufactured by several rivals including the French group Sanofi and US drugmaker Pfizer before it was ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent ...

Recall that no one claims Zantac (ranitidine) itself is harmful. The claim is that under certain (arguably contorted and ...

Settling the cases is not an admission of liability, the company said. Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA ...